Avalo Therapeutics (NASDAQ:AVTX) Now Covered by Analysts at HC Wainwright

HC Wainwright started coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a report published on Thursday, MarketBeat Ratings reports. The firm issued a neutral rating on the stock.

Avalo Therapeutics Price Performance

NASDAQ AVTX opened at $14.44 on Thursday. The firm has a 50-day moving average price of $9.47 and a two-hundred day moving average price of $11.23. Avalo Therapeutics has a 12-month low of $3.95 and a 12-month high of $34.46.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings results on Monday, August 12th. The company reported ($14.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.70) by ($7.37). On average, research analysts predict that Avalo Therapeutics will post -7.78 EPS for the current year.

Institutional Investors Weigh In On Avalo Therapeutics

A number of large investors have recently bought and sold shares of AVTX. Logos Global Management LP bought a new position in shares of Avalo Therapeutics in the 2nd quarter valued at $6,722,000. Ikarian Capital LLC acquired a new stake in Avalo Therapeutics in the first quarter valued at about $1,015,000. Finally, Affinity Asset Advisors LLC grew its position in Avalo Therapeutics by 350.0% in the second quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company’s stock valued at $561,000 after acquiring an additional 35,000 shares during the last quarter. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.